181 related articles for article (PubMed ID: 37286941)
21. Identification of a three-miRNA signature as a novel potential prognostic biomarker in patients with clear cell renal cell carcinoma.
Luo Y; Chen L; Wang G; Xiao Y; Ju L; Wang X
J Cell Biochem; 2019 Aug; 120(8):13751-13764. PubMed ID: 30957284
[TBL] [Abstract][Full Text] [Related]
22. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
[TBL] [Abstract][Full Text] [Related]
23. A Four-Gene Promoter Methylation Marker Panel Consisting of
van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
[No Abstract] [Full Text] [Related]
24. Genome-wide screening and cohorts validation identifying novel lncRNAs as prognostic biomarkers for clear cell renal cell carcinoma.
Zhang C; Huang D; Liu A; Xu Y; Na R; Xu D
J Cell Biochem; 2020 Mar; 121(3):2559-2570. PubMed ID: 31646670
[TBL] [Abstract][Full Text] [Related]
25. A Novel Immune-Related lncRNA-Based Model for Survival Prediction in Clear Cell Renal Cell Carcinoma.
Zhang Z; Tang Y; Liu Y; Zhuang H; Lin E; Xie L; Feng X; Tian K; Zeng J; Liu J; Yu Y
J Immunol Res; 2021; 2021():9921466. PubMed ID: 34368371
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
27. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value of DNA Methylation-Driven Genes in Clear Cell Renal Cell Carcinoma: A Study Based on Methylation and Transcriptome Analyses.
Hu M; Xie J; Hou H; Liu M; Wang J
Dis Markers; 2020; 2020():8817652. PubMed ID: 32733620
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of novel DNA methylation biomarkers for renal clear cell carcinoma.
Kubiliūtė R; Žukauskaitė K; Žalimas A; Ulys A; Sabaliauskaitė R; Bakavičius A; Želvys A; Jankevičius F; Jarmalaitė S
J Cancer Res Clin Oncol; 2022 Feb; 148(2):361-375. PubMed ID: 34689221
[TBL] [Abstract][Full Text] [Related]
30. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.
Deckers IA; Schouten LJ; Van Neste L; van Vlodrop IJ; Soetekouw PM; Baldewijns MM; Jeschke J; Ahuja N; Herman JG; van den Brandt PA; van Engeland M
Clin Cancer Res; 2015 Aug; 21(15):3492-500. PubMed ID: 25904753
[TBL] [Abstract][Full Text] [Related]
31. Identification of methylation-driven genes related to prognosis in clear-cell renal cell carcinoma.
Wang J; Zhang Q; Zhu Q; Liu C; Nan X; Wang F; Fang L; Liu J; Xie C; Fu S; Song B
J Cell Physiol; 2020 Feb; 235(2):1296-1308. PubMed ID: 31273792
[TBL] [Abstract][Full Text] [Related]
32. Identification of a New Prognostic Risk Signature of Clear Cell Renal Cell Carcinoma Based on N
Zhang Y; Yao Y; Qi X; Li J; Liu M; Che X; Xu Y; Wu G
J Immunol Res; 2021; 2021():6617841. PubMed ID: 33628845
[TBL] [Abstract][Full Text] [Related]
33. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
Peng Y; Greenland NY; Lang UE; Stohr BA
Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
[TBL] [Abstract][Full Text] [Related]
35. Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.
Sun JX; Xia QD; Liu CQ; Xu JZ; Xun Y; Lu JL; Hu J; Wang SG
Dis Markers; 2021; 2021():8800358. PubMed ID: 34512816
[TBL] [Abstract][Full Text] [Related]
36. Identification of Ligand-Receptor Pairs Associated With Tumour Characteristics in Clear Cell Renal Cell Carcinoma.
Liu F; Wang P; Sun W; Jiang Y; Gong Q
Front Immunol; 2022; 13():874056. PubMed ID: 35734169
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of a hypoxia-related prognostic signature in clear cell renal cell carcinoma patients.
Li Z; Du G; Zhao R; Yang W; Li C; Huang J; Wen Z; Li H; Zhang B
Medicine (Baltimore); 2021 Oct; 100(39):e27374. PubMed ID: 34596153
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.
van Vlodrop IJ; Baldewijns MM; Smits KM; Schouten LJ; van Neste L; van Criekinge W; van Poppel H; Lerut E; Schuebel KE; Ahuja N; Herman JG; de Bruïne AP; van Engeland M
Am J Pathol; 2010 Feb; 176(2):575-84. PubMed ID: 20042676
[TBL] [Abstract][Full Text] [Related]
39. Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer.
El Khoury LY; Fu S; Hlady RA; Wagner RT; Wang L; Eckel-Passow JE; Castle EP; Stanton ML; Thompson RH; Parker AS; Ho TH; Robertson KD
Clin Epigenetics; 2021 Jan; 13(1):12. PubMed ID: 33461589
[TBL] [Abstract][Full Text] [Related]
40. FCER1G positively relates to macrophage infiltration in clear cell renal cell carcinoma and contributes to unfavorable prognosis by regulating tumor immunity.
Dong K; Chen W; Pan X; Wang H; Sun Y; Qian C; Chen W; Wang C; Yang F; Cui X
BMC Cancer; 2022 Feb; 22(1):140. PubMed ID: 35120484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
